Risk for death significantly lower for patients with return of serum testosterone to normal range value. (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

Kidney stones and gallstones may increase the risk for prostate cancer, which could have implications for disease monitoring and prevention in specific populations. Patients with kidney stones or ...

Risk for death higher for individuals with hospital-based care for alcohol, stimulant, opioids versus cannabis use disorder. (HealthDay News) — Individuals who require hospital-based care for ...

About 44% of respondents said they were willing to participate in a clinical trial. In a survey, less than half of cancer patients and their family members said they were willing to participate in ...

In 2023, 35.6% of patients received androgen-deprivation therapy alone. Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with metastatic hormone ...

The odds of major perioperative bleeding were increased 18.1-fold for patients who underwent emergent hepatic surgery, 10.9-fold for emergent splenic surgery, and 9.6-fold for emergent pancreatic ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

(HealthDay News) — A “Man Van” deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a study presented at the American Society of ...

Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...